Current Edition


CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …

Continue Reading →

Daiichi Sankyo, with tighter focus on oncology, sells 8 aging US cardiovascular drugs to diversifying Cosette

With the acquisition of the U.S. sales and distribution rights of eight cardiovascular drugs from Daiichi Sankyo, Cosette Pharma of New Jersey is making a …

Continue Reading →

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s …

Continue Reading →
clinical trial

Bevacizumab leads clinical trial activity for monoclonal antibodies, says GlobalData

When tracking clinical trial activity across the world, GlobalData, a leading data and analytics company, identified 5,273 industry monoclonal antibodies (mAb) clinical trials with a …

Continue Reading →